Chromium Picolinate
Research Reliability -
A trace mineral supplement that enhances insulin sensitivity, supports healthy blood sugar levels, and reduces carbohydrate cravings.
Appetite
Mood
Sleep
Chromium Picolinate
Description
Chromium picolinate is a highly bioavailable form of chromium that potentiates insulin action, helping cells use glucose more efficiently. It is widely used to support blood sugar regulation in people with insulin resistance, type 2 diabetes, or metabolic syndrome. Research also suggests it can reduce cravings for refined carbohydrates and sweets, making it a useful tool in weight management protocols. Athletes and active individuals may find it helpful for improving body composition by enhancing lean mass relative to fat mass.
Effects
First 2 weeks
subtle
Weeks 4–8
glucose response and cravings may steady
Ongoing
blood sugar support
How it Feels
Some people report fewer sugar cravings within a few weeks; many feel nothing distinct. This is best judged by glucose readings rather than sensation.
Usage
Entry Dose
200mcg
Standard Dose
400–600mcg
Max Dose
1000mcg
Onset
4–8 weeks (glucose)
Combinations
Pairs well with
Synergistic
Berberine — complementary glucose and insulin sensitivity mechanisms
Alpha-lipoic acid — both improve insulin receptor signaling via different pathways
Magnesium — magnesium and chromium both enhance glucose transporter activity
Avoid combining
Contraindicated
Insulin / diabetes medications — may lower blood glucose further; monitor closely
NSAIDs (long-term) — may increase chromium absorption unpredictably
Biomarkers to Track
Subjective
(Daily)
Sugar cravings intensity (1–10)
Energy after meals
Mood and focus after eating
Objective
(Quarterly)
Fasting blood glucose
HbA1c (3-month average glucose)
Fasting insulin level
Generally safe. Can add to the glucose-lowering effect of diabetes medication.
People on blood sugar medication without monitoring, and those with kidney issues.
Expecting dramatic weight loss, and judging it by feel rather than glucose readings.
Preliminary (limited / small human data)
Glycemic effects are small and inconsistent across trials; not a substitute for standard diabetes management.
Suksomboon N et al. (2014). Journal of Clinical Pharmacy and Therapeutics. Meta-analysis (chromium and glycemic control in T2D). PMID: 24635480.